FrancophonIA/ELRC3.0 huggingface dataset:
English: Mundipharma Pharmaceuticals Ltd. Millbank House, Arkle Road Sandyford, Dublin 18 Ireland
Maltese: Millbank House, Arkle Road Sandyford, Dublin 18
English: Denmark Norpharma A/S Slotsmarken 15, Horsholm
Maltese: L-Islanda Norpharma A/S Slotsmarken 15, Horsholm
English: Belgium Mundipharma Comm. VA Blarenberglaan 3C,
Maltese: Il-Belġju Mundipharma Comm. VA Blarenberglaan 3C,
English: C/ Bahía de Pollensa,11, Madrid
Maltese: Mundipharma Pharmaceuticals, S.L. C/ Bahía de Pollensa,11, Madrid
English: C/ Bahía de Pollensa,11 Madrid
Maltese: Mundipharma Pharmaceuticals, S.L. C/ Bahía de Pollensa,11 Madrid
English: Mundipharma Pharmaceuticals Srl Via G. Serbelloni 4, Milano
Maltese: Mundipharma Pharmaceuticals Srl Via G.
English: Luxembourg Mundipharma Comm. VA Blarenberglaan 3C
Maltese: Mundipharma Comm. VA Blarenberglaan 3C Mechelen
English: Mundipharma Pharmaceuticals, S.L.
Maltese: L-Irlanda Mundipharma Pharmaceuticals Ltd.
English: Annex I List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, marketing authorisation holder(s) in the member states
Maltese: Lista tal-ismijiet, għamla farmaċewtika (għamliet farmaċewtiċi), qawwa (qawwiet) tal-prodott(i) mediċinali, mnejn jingħata, id-detentur(i) tal awtorizzazzjoni għat-tqegħid fis-suq fl-istati membri
English: Germany Mundipharma GmbH Mundipharma Str. 2
Maltese: Ir-Rumanija Mundipharma Gesellschaft m.b.H
English: It contains the active substance naldemedine.
Maltese: Fih is-sustanza attiva naldemedina.
English: Rizmoic is available as 200 microgram tablets.
Maltese: Rizmoic jiġi bħala pilloli ta' 200 mikrogramma.
English: Further information on Rizmoic can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/rizmoic
Maltese: ema.europa.eu/medicines/human/EPAR/rizmoic
English: Other information about Rizmoic
Maltese: Informazzjoni oħra dwar Rizmoic
English: What are the risks associated with Rizmoic?
Maltese: X'inhuma r-riskji assoċjati ma' Rizmoic?
English: In two of the studies, involving 1095 patients taking opioids for chronic (long-term) pain caused by a condition other than cancer, 50% of patients taking Rizmoic for 12 weeks achieved the desired outcome, compared with 34% of patients taking placebo.
Maltese: F'żewġ studji minnhom, li kienu jinvolvu 1 095 pazjent li ħadu opjojdi għal uġigħ kroniku (fit-tul) ikkawżat minn kondizzjoni li mhix kanċer, 50 % tal-pazjenti li ħadu Rizmoic għal 12-il ġimgħa kisbu rriżultat mixtieq, meta mqabbla ma' 34 % tal-pazjenti li ħadu l-plaċebo.
English: The active substance in Rizmoic, naldemedine, works by attaching to and blocking receptors in the gut (mu-, delta- and kappa-opioid receptors), through which opioid medicines cause constipation.
Maltese: Is-sustanza attiva f'Rizmoic, in-naldemedina, taħdem billi teħel ma' u timblokka reċetturi fl-imsaren (reċetturi mu-, delta- u kappa-opjojde), li permezz tagħhom il-mediċini opjojde jikkawżaw l-istitikezza.
English: In two other studies, involving 307 patients taking opioids for cancer pain, 74% of patients taking Rizmoic for two weeks achieved the desired outcome compared with 36% of patients taking placebo.
Maltese: F'żewġ studji oħra, li kienu jinvolvu 307 pazjenti li ħadu opjojdi għal uġigħ ikkawżat mill-kanċer, 74 % tal-pazjenti li ħadu Rizmoic għal ġimagħtejn kisbu r-riżultat mixtieq meta mqabbla ma' 36 % talpazjenti li ħadu l-plaċebo.
English: Rizmoic is a medicine for treating constipation caused by opioid pain relief medicines in patients who have previously been treated with a laxative (a medicine that triggers bowel movements).
Maltese: Rizmoic huwa mediċina għall-kura tal-istitikezza kkawżata minn mediċini opjojdi li jtaffu l-uġigħ f'pazjenti li ġew ikkurati qabel b'lassattiv (mediċina li tqanqal movimenti fl-imsaren).
English: As for all medicines, data on the use of Rizmoic are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Rizmoic hija ssorveljata kontinwament.
English: In patients with cancer, the most common side effects were diarrhoea (seen in more than 1 in 10 people) and abdominal pain (seen in up to 1 in 10 people).
Maltese: F'pazjenti li jkollhom kanċer, l-effetti sekondarji l-aktar komuni kienu dijarea (li dehret f'aktar minn persuna 1 minn 10) u wġigħ addominali (li affettwa sa persuna 1 minn 10).
English: What measures are being taken to ensure the safe and effective use of Rizmoic?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' Rizmoic?
English: The most common side effects with Rizmoic in patients without cancer (which may affect up to 1 in 10 people) are abdominal pain (belly ache), diarrhoea, nausea and vomiting.
Maltese: L-effetti sekondarji l-aktar komuni b'Rizmoic f'pazjenti li ma jkollhomx kanċer (li jistgħu jaffettwaw sa persuna 1 minn 10) huma wġigħ addominali (uġigħ ta' żaqq), dijarea, nawżja u remettar.
English: The studies compared Rizmoic with placebo (a dummy treatment) to see if treatment would consistently increase the number of patients who can pass stools and allow them to do so at least 3 times a week during treatment.
Maltese: L-istudji qabblu Rizmoic ma' plaċebo (kura finta) biex jiġi studjat jekk il-kura żżidx b'mod konsistenti n-numru ta' pazjenti li jippurgaw u li jkunu jistgħu jagħmlu dan mill-inqas tliet darbiet fil-ġimgħa matul il-kura.
English: Rizmoic has been shown to improve bowel movement in patients taking opioids pain medicines for long-term pain (including cancer pain).
Maltese: Rizmoic intwera li jtejjeb il-moviment tal-imsaren f'pazjenti li jieħdu mediċini opjojdi kontra l-uġigħ għal uġigħ fit-tul (inkluż uġigħ ikkawżat mill-kanċer).
English: How is Rizmoic used?
Maltese: Kif jintuża Rizmoic?
English: Side effects reported with Rizmoic are carefully evaluated and any necessary action taken to protect patients.
Maltese: L-effetti sekondarji rrappurtati b'Rizmoic huma evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex tipproteġi lill-pazjenti.
English: The majority of side effects in patients with or without cancer were mild to moderate.
Maltese: Il-maġġoranza tal-effetti sekondarji f'pazjenti li kellhom kanċer jew li ma kellhomx kanċer kienu ħfief sa moderati.
English: Constipation is the most common side effect of opioid pain medicines and many standard laxatives are not effective in treating the condition.
Maltese: L-istitikezza hija l-effett sekondarju l-aktar komuni ta' mediċini opjojdi kontra l-uġigħ u ħafna lassattivi standard mhumiex effettivi biex jikkuraw il-kondizzjoni.
English: Slabinská 30, 03680 Martin Slovakia
Maltese: Slabinská 30, 03680 Martin Is-Slovakkja
English: UNIQUE IDENTIFIER - 2D BARCODE
Maltese: IDENTIFIKATUR UNIKU - BARCODE 2D 18.
English: Memantine did not inhibit CYP 1A2, 2A6, 2C9, 2D6, 2E1, 3A, flavin containing monooxygenase, epoxide hydrolase or sulphation in vitro.
Maltese: Memantine ma fixkelx CYP 1A2, 2A6, 2C9, 2D6, 2E1, 3A, monoxygenase li fih flavin, epoxide hydrolase jew sulfejxin in vitro.
English: ● dopaminergic agonists (substances such as L-dopa, bromocriptine)
Maltese: • agonisti dopaminerġiċi ( sustanzi bħal L-dopa, bromocriptine)
English: Common Common Uncommon Very rare
Maltese: Komuni Komuni Mhux komuni Rari ħafna
English: SL-03680 Martin Slovakia
Maltese: SL-03680
English: Week 3 (day 15-21):
Maltese: (jum 15-21):
English: ● hydrochlorothiazide (or any combination with hydrochlorothiazide)
Maltese: • hydrochlorothiazide (jew kwalunkwe kombinazzjoni ma' hydrochlorothiazide)
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 13 June 2013
Maltese: DATA TAL-EWWEL AWTORIZZAZZJONI/TIĠDID TAL-AWTORIZZAZZJONI Data tal-ewwel awtorizzazzjoni: 13 ta' Ġunju 2013
English: This medicine contains soya lecithin.
Maltese: Din il-mediċina fiha soya lecithin.
English: The most frequently occurring adverse reactions with a higher incidence in the memantine group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%).
Maltese: L-aktar każijiet b'reazzjonijiet avversi li seħħew ta' spiss fil-grupp ta' memantine milli filgrupp tal-plaċebo kienu sturdament (6.3% vs 5.6%, rispettivament), uġigħ ta' ras (5.2% vs 3.9%), stitikezza (4.6% vs 2.6%), ngħas (3.4% vs 2.2%) u pressjoni għolja (4.1% vs 2.8%).
English: Memantine ratiopharm contains soya lecithin, see section 4.3.
Maltese: Memantine ratiopharm fih soya lecithin, ara sezzjoni 4.3.
English: Constipation Vomiting Pancreatitis2
Maltese: Stitikezza Rimettar Pankrejatite2
English: - Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Maltese: - Sustanzi attivi oħra bħal cimetidine, ranitidine, procainamide, quinidine, quinine u nicotine, li jużaw l-istess sistema ta' trasport ketajoniku renali bħal amantadine, jistgħu ukoll jinteraġixxu ma' memantine u b'hekk jista' jkun hemm riskju ta' livelli ogħla fil-plażma.
English: Week 2 (day 8-14):
Maltese: Ġimgħa 2 (jum 8-14)
English: Common (affects 1 to 10 users in 100):
Maltese: Komuni (jaffettwa minn 1 sa 10 utenti f'100):
English: Main human metabolites are N-3,5-dimethyl-gludantan, the isomeric mixture of 4-and 6-hydroxymemantine, and 1-nitroso-3,5-dimethyl-adamantane.
Maltese: Il-metaboli ewlenin fil-bniedem huma N-3,5-dimethyl-gludantan, it-taħlita ta' 4- u 6-hydroxy-memantine, u 1-nitroso-3,5-dimethyl-adamantane.
English: Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Maltese: Ir-reazzjonijiet avversi huma mniżżla skont is-sistema tal-klassifika tal-organi, bil-konvenzjoni li ġejja: komuni ħafna (≥1/10) komuni (≥1/100 sa <1/10), mhux komuni (≥1/1,000 sa <1/100), rari (≥1/10,000 sa <1/1,000), rari ħafna (<1/10,000), mhux magħruf (ma tistax tittieħed stima mid-data disponibbli).
English: Week 4 (day 22-28):
Maltese: Ġimgħa 4 (jum 22-28)
English: Memantine ratiopharm is available in packs with 28 (7 +7 +7 + 7) film-coated tablets.
Maltese: Memantine ratiopharm hu disponibbli f'pakketti bi 28 (7 +7 +7 + 7) pillola miksija b'rita.
English: 20 days, more than 99% being excreted renally.
Maltese: 20 jum, li minnha aktar minn 99% tneħħiet ma' l-awrina.
English: Paediatric population No data available.
Maltese: M'hemm l-ebda data disponibbli.
English: ● dextromethorphan (generally used to treat cough) and
Maltese: • dextromethorphan (ġeneralment użat għas-sogħla) u
English: Psychotic reactions2
Maltese: Alluċinazzjonijiet1 Reazzjonijiet psikotiċi2
English: Week 1 (day 1-7):
Maltese: Ġimgħa 1 (jum 1-7)
English: ● amantadine (for the treatment of Parkinson's disease),
Maltese: • amantadine (għat-trattament tal-marda ta' Parkinson),
English: Manufacturer Merckle GmbH Ludwig-Merckle-Straße 3 89143 Blaubeuren Germany
Maltese: Merckle GmbH Ludwig-Merckle-Straße 3 89143 Blaubeuren Il-Ġermanja
English: In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance-active substance interaction of memantine with glyburide/metformin or donepezil was observed.
Maltese: Fi studji farmakokinetiċi b'doża waħda (PK) f'żgħażagħ b'saħħithom, ma kienx hemm interazzjoni bejn sustanza attiva u oħra ta' memantine ma' glyburide/metformin jew donepezil.
English: for 7 days.
Maltese: 6 xhur.
English: Uncommon (affects 1 to 10 users in 1,000):
Maltese: Mhux komuni (jaffettwa minn 1 sa 10 utenti f'1,000 ):
English: Memantine ratiopharm contains lactose.
Maltese: Memantine ratiopharm fih lactose.
English: PVC/PVDC-Aluminium foil blister packs Pack sizes of 28 (7 +7 +7 + 7) film-coated tablets.
Maltese: In-natura tal-kontenitur u ta' dak li hemm ġo fih Pakketti b'folji b'fojl tal-PVC/PVDC-Aluminju Daqsijiet tal-pakketti ta' 28 (7 +7 +7 + 7) pillola miksija b'rita.
English: The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer's disease cooperative study - activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
Maltese: L-istudju wera effetti tajbin tal-kura b'memantine meta mqabbla ma' plaċebo mas-6 xahar (analiżi tal-każijiet għall-impressjoni ta' bidla skont l-intervista tat-tabib (CIBIC-plus): p=0.025; studju kooperattiv tal-marda ta' Alzheimer (ADCS-ADLsev): p=0.003; Batterija ta' indeboliment sever (SIB): p=0.002).
English: ● ketamine (a substance generally used as an anaesthetic),
Maltese: • ketamine (sustanza li ġeneralment tingħata bħala loppju),
English: Do not take Memantine ratiopharm:
Maltese: Tiħux Memantine ratiopharm:
English: HDPE (high-density polyethylene) bottles with PP (polypropylene) caps Pack sizes of 100 film-coated tablets.
Maltese: Fliexken tal-HDPE (polyethylene ta' densità għolja) bl-għatu tal-PP (polypropylene) Daqsijiet tal-pakketti ta' 100 pillola miksija b'rita.
English: In the overdose cases below 140 mg or unknown dose the patients revealed symptoms from central nervous system (confusion, drowsiness, somnolence, vertigo, agitation, aggression, hallucination, and gait disturbance) and/or of gastrointestinal origin (vomiting and diarrhoea).
Maltese: Fil-każijiet ta' doża eċċessiva taħt il-140 mg, jew doża mhux magħrufa, il-pazjenti wrew sintomi li kienu ġejjin missistema nervuża ċentrali (konfużjoni, tħeddil, ngħas, vertiġini, aġitazzjoni, aggressjoni, alluċinazzjoni, u disturbi fil-qagħda tal-mixi) u/jew ta' natura gastro-intestinali (rimettar u dijarea).
English: Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer's disease assessment scale (ADAS-cog) (p=0.003) and CIBIC-plus (p=0.004) at week 24 (last observation carried forward (LOCF)).
Maltese: Skala ta' assessjar tal-marda ta' Alzheimer ADAS-cog (p=0.003) u CIBIC-plus (p=0.004) f' Ġimgħa 24 bl-aħħar osservazzjoni miġjuba 'l quddiem (LOCF).
English: Renal handling also involves tubular reabsorption, probably mediated by cation transport proteins.
Maltese: Proċess renali ieħor jinvolvi ri-assorbiment tubulari, probabbilment permezz ta' proteini ta' trasport katajoniċi.
English: EU/1/13/836/001 10 film-coated tablets EU/1/13/836/002 14 film-coated tablets EU/1/13/836/003 21 film-coated tablets EU/1/13/836/004 28 film-coated tablets EU/1/13/836/005 30 film-coated tablets EU/1/13/836/006 42 film-coated tablets EU/1/13/836/007 50 film-coated tablets EU/1/13/836/008 56 film-coated tablets EU/1/13/836/009 98 film-coated tablets EU/1/13/836/010 100 film-coated tablets EU/1/13/836/011 112 film-coated tablets
Maltese: EU/1/13/836/001 10 pilloli miksija b'rita EU/1/13/836/002 14-il pillola miksija b'rita EU/1/13/836/003 21 pillola miksija b'rita EU/1/13/836/004 28 pillola miksija b'rita EU/1/13/836/005 30 pillola miksija b'rita EU/1/13/836/006 42 pillola miksija b'rita EU/1/13/836/007 50 pillola miksija b'rita EU/1/13/836/008 56 pillola miksija b'rita EU/1/13/836/009 98 pillola miksija b'rita EU/1/13/836/010 100 pillola miksija b'rita EU/1/13/836/011 112-il pillola miksija b'rita
English: Maintenance dose The recommended maintenance dose is 20 mg per day.
Maltese: Doża ta' manteniment Id-doża ta' manteniment rrakkomandata hi ta' 20 mg kuljum.
English: Memantine ratiopharm contains the active substance memantine hydrochloride.
Maltese: Memantine ratiopharm fih is-sustanza attiva memantine hydrochloride.
English: When daily doses of 5 to 30 mg were administered, a mean cerebrospinal fluid (CSF)/serum ratio of 0.52 was calculated.
Maltese: Meta ngħataw dożi ta' 5 sa 30 mg kuljum, il-proporzjon tal-medja ta' fluwidu ċerebrospinali CSF/serum kien ikkalkolat 0.52.
English: The patient experienced central nervous system symptoms such as restlessness, psychosis, visual hallucinations, proconvulsiveness, somnolence, stupor, and unconsciousness.
Maltese: Il-pazjent kellu sintomi tas-sistema nervuża ċentrali fosthom, irrikwitezza, psikożi, alluċinazzjonijiet tal-vista, pro-aċċessjonijiet, ngħas, sturdament u intilef minn sensih.
English: EU/1/13/836/013 10 film-coated tablets EU/1/13/836/014 14 film-coated tablets EU/1/13/836/015 21 film-coated tablets EU/1/13/836/016 28 film-coated tablets EU/1/13/836/017 30 film-coated tablets EU/1/13/836/018 42 film-coated tablets EU/1/13/836/019 56 film-coated tablets EU/1/13/836/020 98 film-coated tablets EU/1/13/836/021 100 film-coated tablets
Maltese: EU/1/13/836/013 10 pilloli miksija b'rita EU/1/13/836/014 14-il pillola miksija b'rita EU/1/13/836/015 21 pillola miksija b'rita EU/1/13/836/016 28 pillola miksija b'rita EU/1/13/836/017 30 pillola miksija b'rita EU/1/13/836/018 42 pillola miksija b'rita EU/1/13/836/019 56 pillola miksija b'rita EU/1/13/836/020 98 pillola miksija b'rita EU/1/13/836/021 100 pillola miksija b'rita
English: Memantine ratiopharm contains lactose and soya lecithin This medicine contains lactose.
Maltese: Memantine ratiopharm fih lactose u soya lecithin Din il-mediċina fiha l-lactose.
English: Each pack of 28 film-coated tablets for a 4 week treatment schedule contains: 7 x 5 mg and 7 x 10 mg and 7 x 15 mg and 7 x 20 mg film-coated tablets
Maltese: Kull pakkett ta' 28 pillola miksija b'rita għal skeda ta' kura ta' 4 ġimgħat fih: 7 x 5 mg u 7 x 10 mg u 7 x 15 mg u 7 x 20 mg pilloli miksija b'rita
English: In case of signs and symptoms of general central nervous system (CNS) overstimulation, careful symptomatic clinical treatment should be considered.
Maltese: F'każ ta' sinjali u sintomi ta' stimulazzjoni ġenerali eċċessiva tas-Sistema Nervuża Ċentrali (SNĊ), għandha titqies kura klinika tas-sintomi bir-reqqa.
English: In clinical trials in mild to severe dementia, involving 1,784 patients treated with memantine and 1,595 patients treated with placebo, the overall incidence rate of adverse reactions with memantine did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity.
Maltese: Fi provi kliniċi f'pazjenti b'dimenzja ħafifa għal moderata, b'1,784 pazjent ikkurati b'memantine u 1,595 pazjent ikkurati bi plaċebo, ir-rata globali ta' reazzjonijiet avversi li seħħew b'memantine ma kinitx differenti min dik tal-plaċebo; ir-reazzjoniiet avversi ġeneralment kienu ħfief għal moderati filqawwa.
English: The patient had received 400 mg memantine orally.
Maltese: Il-pazjent kien ingħata 400 mg memantine b'mod orali.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 5 mg or 10 mg or 15 mg or 20 mg of memantine hydrochloride equivalent to 4.15 mg or 8.31 mg or 12.46 mg or 16.62 mg memantine.
Maltese: Kull pillola miksija b'rita fiha 5 mg jew 10 mg jew 15 mg jew 20 mg ta' memantine hydrochloride ekwivalenti għal 4.15 mg jew 8.31 mg jew 12.46 mg jew 16.62 mg ta' memantine.
English: Blister packs Do not store above 25°C.
Maltese: Taħżinx f'temperatura 'l fuq minn 25°C.
English: ● Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure and venous blood clotting (thrombosis/thromboembolism)
Maltese: • Għeja, infezzjonijiet tal-moffa, konfużjoni, alluċinazzjonijiet, rimettar, mixja anormali,
English: Daily doses of 20 mg lead to steady-state plasma concentrations of memantine ranging from 70 to 150 ng/ml (0.5-1 μmol) with large interindividual variations.
Maltese: Dożi ta' 20 mg kuljum wasslu għal konċentrazzjonijiet ta' memantine fil-plażma fi stat fiss f'medda ta' bejn 70 sa 150 ng/ml (0.5 - 1 µmol) b'varjazzjonijiet kbar bejn individwu.u ieħor.
English: - There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co-administered with HCT or any combination with HCT.
Maltese: - Jista' jkun hemm possibilità ta' livelli ta' hydrochlorthiazide (HCT) imnaqqsa fis-serum meta memantine jingħata ma' HCT jew kwalunkwe taħlita li fiha HCT.
English: A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer's disease (mini mental state examination (MMSE) total scores at baseline of 3-14) included a total of 252 outpatients.
Maltese: Studju pivitali b'terapija waħda f'popolazzjoni ta' pazjenti li kienu qed ibatu mill-marda ta' Alzheimer moderata għal severa (eżami żgħir ħafna ta' l-istat mentali (MMSE) punteġġ totali fil-linja bażi ta' 3-14) kien jinkludi 252 outpatient.
English: Starch pregelatinised (E 1404)
Maltese: Cellulose microcrystalline (E 460) Starch pregelatinised (E 1404)
English: PVC/PVDC-Aluminium foil blister packs Pack sizes of 10, 14, 21, 28, 30, 42, 50, 56, 98, 100, 112 film-coated tablets.
Maltese: Pakketti b'folji b'fojl tal-PVC/PVDC-Aluminju Daqsijiet tal-pakketti ta' 10, 14, 21, 28, 30, 42, 50, 56, 98, 100, 112-il pillola miksija b'rita.
English: There is one published case report on a possible risk also for the combination of memantine and phenytoin.
Maltese: Hemm rapport wieħed ta' każ li kien ippublikat dwar riskju li jista' jkun hemm meta memantine jingħata ma' phenytoin.
English: PVC/PVDC-Aluminium foil blister packs Pack sizes of 10, 14, 21, 28, 30, 42, 56, 98, 100 film-coated tablets.
Maltese: Pakketti b'folji b'fojl tal-PVC/PVDC-Aluminju Daqsijiet tal-pakketti ta' 10, 14, 21, 28, 30, 42, 56, 98, 100 pillola miksija b'rita.
English: Other medicines and Memantine ratiopharm
Maltese: Mediċini oħra u Memantine ratiopharm
English: 10 film-coated tablets 14 film-coated tablets 21 film-coated tablets 28 film-coated tablets 30 film-coated tablets 42 film-coated tablets 50 film-coated tablets 56 film-coated tablets 98 film-coated tablets 100 film-coated tablets 112 film-coated tablets
Maltese: 10 pilloli miksija b'rita 14-il pillola miksija b'rita 21 pillola miksija b'rita 28 pillola miksija b'rita 30 pillola miksija b'rita 42 pillola miksija b'rita 50 pillola miksija b'rita 56 pillola miksija b'rita 98 pillola miksija b'rita 100 pillola miksija b'rita 112-il pillola miksija b'rita
English: No adverse reactions of memantine were noted on male and female fertility.
Maltese: Ma ġew osservati l-ebda reazzjonijiet avversi ta' memantine fuq il-fertilità maskili u femminili.
English: In patients with moderate renal impairment (creatinine clearance 30-49 ml/min) daily dose should be 10 mg per day.
Maltese: F'pazjenti b'indeboliment renali moderat (tneħħija tal-kreatinina 30 - 49 ml/min) id-doża għandha tkun 10 mg kuljum.
English: EU/1/13/836/001 EU/1/13/836/002 EU/1/13/836/003 EU/1/13/836/004 EU/1/13/836/005 EU/1/13/836/006 EU/1/13/836/007 EU/1/13/836/008 EU/1/13/836/009 EU/1/13/836/010 EU/1/13/836/011 EU/1/13/836/012 EU/1/13/836/013 EU/1/13/836/014 EU/1/13/836/015 EU/1/13/836/016 EU/1/13/836/017 EU/1/13/836/018 EU/1/13/836/019 EU/1/13/836/020 EU/1/13/836/021 EU/1/13/836/022
Maltese: EU/1/13/836/005 EU/1/13/836/006 EU/1/13/836/007 EU/1/13/836/008 EU/1/13/836/009 EU/1/13/836/010
English: Memantine ratiopharm is available in packs of 10, 14, 21, 28, 30, 42, 50, 56, 98, 100 and 112 filmcoated tablets.
Maltese: Memantine ratiopharm hu disponibbli f'pakketti ta' 10, 14, 21, 28, 30, 42, 50, 56, 98, 100 u 112il pillola miksija b'rita.
English: Colloidal anhydrous silica (E 551)
Maltese: Colloidal anhydrous silica (E 551) Magnesium stearate (E 470b)
English: 10 film-coated tablets 14 film-coated tablets 21 film-coated tablets 28 film-coated tablets 30 film-coated tablets 42 film-coated tablets 56 film-coated tablets 98 film-coated tablets 100 film-coated tablets
Maltese: 10 pilloli miksija b'rita 14-il pillola miksija b'rita 21 pillola miksija b'rita 28 pillola miksija b'rita 30 pillola miksija b'rita 42 pillola miksija b'rita 56 pillola miksija b'rita 98 pillola miksija b'rita 100 pillola miksija b'rita